Biyoteknolojinin sinir bilim uygulamalarında gelinen nokta: Üstinsan mı, biyolojik robot mu?

Sinirbilim alanında kullanılan son teknolojiler (fonksiyonel beyin görüntülemesi, ruhsal durum ve beyin fonksiyonları üzerinde etkili ilaçlar, beyin yapısı, fonksiyonu ve düzeni ile ilgili araçlar) birçok etik sorunun tartışılmasına neden olmaktadır. Bu sorunlardan en önemlisi; bu teknolojilerin herhangi bir tıbbi endikasyon olmadan, bireylerin zihinsel ve beyinsel yetenek ve kapasitelerinin geliştirilmesi veya güçlendirilmesi amacıyla kullanılmasıdır. Beyinsel kapasitenin veya yeteneğin geliştirilmesi veya güçlendirilmesi, tıbbın tedavi edici rolünün ötesinde, farklı amaçlar için kullanılmasına neden olacağı için, etik, sosyal ve felsefik endişelere neden olmaktadır.

Anahtar Kelimeler:

Biyoetik, Biyoteknoloji, Etik, Sinirbilim, Etik teori

The position of biotechnology in neuroscience: The overman (Übermensch) or biological robot?

Emerging neurotechnologies, including psychopharmaceuticals, brain stimulation, implantable brain chips, transcranial magnetic stimulation, and brain imaging raise a number of ethical questions. One of the most contentious is the proper role of these technologies in improving or increasing mental and neurological traits and skills in those with no identifiable pathology. The "enhancement" debate centers around a number of ethical, sosical and philosophical concerns to the proper role of medicine, therapeutics, and desirable human qualities.

Keywords:

Bioethics, Biotechnology, Ethics, Neurosciences, Ethical Theory,

PDF

___

1. Neuroethics: Mapping the Field, a conference for neuroscientists, bioethicists, doctors of psychiatry and psychology, philosophers, and professors of law and public policy in San Francisco, CA, sponsored by the Dana Foundation on May 13-15, 2002.
2. Safire W. Vision for a New Field of Neuroethics. Neuroethics: Mapping the Field, a conference for neuroscientists, bioethicists, doctors of psychiatry and psychology, philosophers, and professors of law and public policy in San Francisco, CA, sponsored by the Dana Foundation on May 13-15, 2002. p: 3-9.
3. Glannon W. Neuroethics Background Briefing Bioethics. 2006 February; 20 (1):37-52.
4. Neuroethics: Mapping the Field, a conference for neuroscientists, bioethicists, doctors of psychiatry and psychology, philosophers, and professors of law and public policy in San Francisco, CA, sponsored by the Dana Foundation on May 13-15, 2002. p: 122.
5. Farah, M.J. Emerging ethical issues in neuroscience. Natural. Neuroscience, 2002 (5), 1123-1129.
6. Cabeza R, Rao SM, Wagner AD, Mayer AR, Schacter DL. Can medial temporal lobe regions distinguish true from false? An event-related functional MRI study of veridical and illusory recognition memory. Proc. Natl. Acad. Sci. U S A. 2001 April, 10;98 (8):4805-10.
7. Greene JD, Sommerville RB, Nystrom LE, Darley JM, Cohen JD. An fMRI investigation of emotional engagement in moral judgment. Science. 2001 September, 14; 293 (5537):1971-2.
8. Ida Gobbini M, Leibenluft E, Santiago N, Haxby JV. Social and emotional attachment in the neural representation of faces. Neuroimage. 2004 August; 22 (4):1628-35.
9. Judy Illes, Eric Racine. Imaging or Imagining? A Neuroethics Challenge Informed by Genetics. American Journal of Bioethics, Volume 5, Number 2 / March-April 2005.p: 5 – 18.
10. Langleben DD, Schroeder L, Maldjian JA, Gur RC, McDonald S, Ragland JD, O'Brien CP, Childress AR. Brain activity during simulated deception: an event-related functional magnetic resonance study. Neuroimage. 2002 Mar;15 (3):727-32.
11. Thomas E. Beam, Edmund G. Howe: Military Medical Ethics. Uniformed Services University of the Health Science, Bethesda, Meryland, 2003. Vol: 2, p: 831-55.
12. Wolpe PR.Treatment, enhancement, and the ethics of neurotherapeutics. Brain Cogn. 2002 December; 50 (3):387-95.
13. Andrews W.1; Parker G.; Barrett E. The SSRI antidepressants: Exploring their ''other'' possible properties. Journal of Affective Disorders, Volume 49, Number 2, May 1998, pp. 141-144.
14. Teitelman E. Off-label uses of modafinil. Am. J. Psychiatry. 2001 Jun;158 (6):970-1.
15. Wangsness M. Pharmacological treatment of obesity. Past, present, and future. Minn. Med. 2000 November; 83 (11):21-6.
16. Martha J. Farah: Brain-Machine Interfaces and Non-pharmacological Enhancement. Natural Neuroscience. 2002 November; 5 Suppl:1085-8.